Albany, NY -- (SBWire) -- 11/27/2017 --Transparency Market Research (TMR) has announced the publication of a new market research report on the preimplantation genetic diagnosis. Statistics mentioned in the report suggest that the global preimplantation genetic diagnosis market was valued at US$77.2 million in 2013 and is expected to reach US$118.0 million by 2020, growing a CAGR of 6.28% from 2014 to 2020. The report, titled "Preimplantation Genetic Diagnosis Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020", offers an in-depth understanding of the global preimplantation genetic diagnosis market, its growth drivers, market restraints, and potential growth opportunities in the coming future.

According to market research report published by Transparency Market Research, the global preimplantation genetic diagnosis (PGD) market is witnessing stupendous growth due to rise of infertility, which leads to a delayed conception and a higher risk of genetic diseases. Reasons such as the desire to give birth to a disease-free offspring are pushing infertile patients to go through PGD cycle. The other factor driving the global preimplantation genetic diagnosis (PGD) market is the possibility of the offspring having a genetic predisposition to cardiac diseases and the capability of PGD to diagnose rare diseases such as fibrodysplasia ossificans progressive (FOP). The desire of the healthcare community to bring up a generation that is free of diseases is the primary reason for the growth of the global preimplantation genetic diagnosis (PGD) market.

Read Report Overview @ https://www.transparencymarketresearch.com/preimplantation-genetic-diagnosis-market.html

In terms of geography, Europe held the biggest market share, at over 50% in 2013. The alarming rate of infertility in Europe due to unhealthy lifestyle choices such as excessive alcohol intake, smoking, and substance abuse has made Europe the leading regional preimplantation genetic diagnosis market. Smoking excessively or for a long time can have serious repercussions on pregnancy. Smokers are at a much higher risk of giving birth to offspring with abnormalities. Such risks are prompting patients to opt for PGD as well.

The aneuploidy screening test segment of the global preimplantation genetic diagnosis (PGD) market held a market share of 36% in 2013. This test is used for counting the number of chromosomes. It reduces the chances of transferring an embryo that may have a chromosomal abnormality. Additionally, liberal regulations in several countries permit PGD for aneuploidy screening and are thus adding to the growth prospects of aneuploidy screening.

Request Sample Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=427

PGD for human leukocyte antigen (HLA typing) is also one of the rapidly growing test types in this market. This test is conducted on an embryo that is then tissue matched and donated to the stem cells of its ailing sibling. This test is a boon for children who have siblings suffering from X-linked adrenoleukodystrophy (X-ALD), sickle cell anemia, ?-thalassaemia, and Fanconi anemia, and X-linked hypohidrotic ectodermal dysplasia with an immune deficiency (HED-ID). The growing incidences of these diseases and increasing awareness of HLA typing is also expected to boost its market share in the same period.

Some of the key players in the global preimplantation genetic diagnosis market are Genesis Genetics Ltd., Illumina, Inc., Genea Ltd., Natera, Inc., Laboratory Corporation of America Holdings, PerkinElmer, Inc., Reprogenetics, LLC, Quest Diagnostics, Inc., and Reproductive Genetics Institute.

About Transparency Market Research (TMR)
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR's experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR's syndicated reports strive to provide clients to serve their overall research requirement.